These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 28337672)

  • 1. Fentanyl Formulations in the Management of Pain: An Update.
    Schug SA; Ting S
    Drugs; 2017 May; 77(7):747-763. PubMed ID: 28337672
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New formulations of fentanyl for acute pain management.
    Paech MJ; Bloor M; Schug SA
    Drugs Today (Barc); 2012 Feb; 48(2):119-32. PubMed ID: 22384452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of non-intravenous formulations of fentanyl.
    Lötsch J; Walter C; Parnham MJ; Oertel BG; Geisslinger G
    Clin Pharmacokinet; 2013 Jan; 52(1):23-36. PubMed ID: 23100195
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Formulations of fentanyl for the management of pain.
    Grape S; Schug SA; Lauer S; Schug BS
    Drugs; 2010; 70(1):57-72. PubMed ID: 20030425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A patient-activated iontophoretic transdermal system for acute pain management with fentanyl hydrochloride: overview and applications.
    Bain KT
    J Opioid Manag; 2006; 2(6):314-24. PubMed ID: 17326593
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intranasal fentanyl spray: a novel dosage form for the treatment of breakthrough cancer pain.
    Dietrich E; Gums JG
    Ann Pharmacother; 2012 Oct; 46(10):1382-91. PubMed ID: 23012382
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transmucosal Immediate-Release Fentanyl for Breakthrough Cancer Pain: Opportunities and Challenges for Use in Palliative Care.
    Chang A; Roeland EJ; Atayee RS; Revta C; Ma JD
    J Pain Palliat Care Pharmacother; 2015 Sep; 29(3):247-60. PubMed ID: 26368648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Iontophoretic transdermal fentanyl for the management of acute perioperative pain in hospitalized patients.
    Fanelli A; Sorella MC; Chelly JE
    Expert Opin Pharmacother; 2016; 17(4):571-7. PubMed ID: 26809270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The fentanyl HCl patient-controlled transdermal system (PCTS): an alternative to intravenous patient-controlled analgesia in the postoperative setting.
    Sinatra R
    Clin Pharmacokinet; 2005; 44 Suppl 1():1-6. PubMed ID: 16156110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fentanyl for breakthrough pain: a systematic review.
    Davis MP
    Expert Rev Neurother; 2011 Aug; 11(8):1197-216. PubMed ID: 21797660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of dosing frequency on the pharmacokinetics of a fentanyl HCl patient-controlled transdermal system (PCTS).
    Sathyan G; Zomorodi K; Gidwani S; Gupta S
    Clin Pharmacokinet; 2005; 44 Suppl 1():17-24. PubMed ID: 16156112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and pharmacokinetic considerations of novel formulations of fentanyl for breakthrough cancer pain.
    Chen C; Gupta A
    Pain Manag; 2014; 4(5):339-50. PubMed ID: 25350074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
    Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An iontophoretic, fentanyl HCl patient-controlled transdermal system for acute postoperative pain management.
    Chelly JE
    Expert Opin Pharmacother; 2005 Jun; 6(7):1205-14. PubMed ID: 15957973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacodynamics and clinical efficacy of fentanyl iontophoretic transdermal system for post-operative pain in hospitalized patients.
    Skledar SJ; Lachell CM; Chelly JE
    Expert Opin Drug Metab Toxicol; 2015; 11(12):1925-35. PubMed ID: 26565744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current practices for postoperative pain management in Europe and the potential role of the fentanyl HCl iontophoretic transdermal system.
    Rawal N; Langford RM
    Eur J Anaesthesiol; 2007 Apr; 24(4):299-308. PubMed ID: 17156510
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A review of the pharmacokinetic profile of transmucosal fentanyl formulations.
    Moore N; Darwish M; Amores X; Schneid H
    Curr Med Res Opin; 2012 Nov; 28(11):1781-90. PubMed ID: 23020252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of fentanyl HCl iontophoretic transdermal system compared with morphine intravenous patient-controlled analgesia for postoperative pain management for patient subgroups.
    Mattia C; Coluzzi F; Sonnino D; Anker-Møller E
    Eur J Anaesthesiol; 2010 May; 27(5):433-40. PubMed ID: 20186064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fast-acting fentanyl preparations and pain management.
    McWilliams K; Fallon M
    QJM; 2013 Oct; 106(10):887-90. PubMed ID: 23613597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Danish pain specialists' rationales behind the choice of fentanyl transdermal patches and oral transmucosal systems--a delphi study.
    Jacobsen R; Møldrup C; Christrup L
    Pain Med; 2009 Nov; 10(8):1442-51. PubMed ID: 19793344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.